Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01304303 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
A Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT01304303 is a Phase 1 study that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 57 participants.
The verdict
NCT01304303, a Phase 1 study, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
Phase I study of SPARC1023 alone and in combination with carboplatin
Interventions
- DRUG SPARC1023 I
- DRUG SPARC1023 II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01304303
The ClinicalTrials.gov registry entry for NCT01304303 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sun Pharma Advanced Research Company Limited, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SPARC1023 I is the first listed.
NCT01304303 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01304303 about?
NCT01304303 is a clinical study titled "Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination". Phase I study of SPARC1023 alone and in combination with carboplatin
What is the current status of trial NCT01304303?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2011-10. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01304303?
The interventions under investigation include: SPARC1023 I (DRUG), SPARC1023 II (DRUG).
Who is sponsoring clinical trial NCT01304303?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.